{"entity":{"id":"paper-checkmate-76k-nat-med-2023","kind":"paper","name":"CheckMate 76K: adjuvant nivolumab in resected stage IIB or IIC melanoma","aka":[],"tldr":"Adjuvant nivolumab for a year after surgery cut the risk of recurrence by more than half in stage IIB and IIC melanoma, confirming the benefit seen with pembrolizumab in the same setting.","summary":"Phase 3 placebo-controlled trial of 790 patients with completely resected stage IIB or IIC melanoma randomised 2:1 to nivolumab or placebo for 12 months.\n\nTwelve-month recurrence-free survival was 89.0 versus 79.4 percent (hazard ratio 0.42), with benefit across subgroups and a distant metastasis-free survival hazard ratio of 0.47; treatment-related grade 3 to 4 adverse events occurred in 10.3 percent.","asOf":"2026-09-17","links":[{"label":"Nat Med 2023","url":"https://doi.org/10.1038/s41591-023-02583-2"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/37845511/"}],"tags":[],"related":[],"cancers":["stage-ii-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04099251"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature-medicine"],"dependsOn":[],"notes":[],"journal":"Nature Medicine","year":2023,"doi":"10.1038/s41591-023-02583-2","pmid":"37845511","authors":"Kirkwood JM, Del Vecchio M, Weber J, et al.","paperType":"rct","findings":["Twelve-month recurrence-free survival 89.0 percent vs 79.4 percent; hazard ratio 0.42.","Distant metastasis-free survival hazard ratio 0.47."],"whatItMeans":"Nivolumab is a second approved adjuvant option for stage IIB and IIC melanoma with the same trade-offs as pembrolizumab.","caveats":["Short follow-up at primary analysis; no survival data."],"changedPractice":true,"participants":790},"route":"/key-papers/paper-checkmate-76k-nat-med-2023/","neighbours":{"cancer":[{"id":"stage-ii-melanoma","kind":"cancer","name":"Stage IIB and IIC melanoma","route":"/cancers/stage-ii-melanoma/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"trial":[{"id":"nct04099251","kind":"trial","name":"Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma","route":"/trials/nct04099251/"}],"journal":[{"id":"nature-medicine","kind":"journal","name":"Nature Medicine","route":"/journals/nature-medicine/"}]}}